Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Acumen Pharmaceuticals (ABOS)

Acumen Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ABOS
DateTimeSourceHeadlineSymbolCompany
26/11/202421:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
12/11/202421:29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABOSAcumen Pharmaceuticals Inc
12/11/202412:00GlobeNewswire Inc.Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business HighlightsNASDAQ:ABOSAcumen Pharmaceuticals Inc
11/11/202421:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the Stifel Healthcare ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
06/11/202422:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
06/11/202422:24Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
06/11/202421:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the UBS Global Healthcare ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
06/11/202413:00GlobeNewswire Inc.Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of QualityNASDAQ:ABOSAcumen Pharmaceuticals Inc
05/11/202421:00GlobeNewswire Inc.Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
31/10/202412:05GlobeNewswire Inc.Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
23/10/202412:00GlobeNewswire Inc.Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
30/09/202420:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
26/09/202412:00GlobeNewswire Inc.Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s DiseaseNASDAQ:ABOSAcumen Pharmaceuticals Inc
25/09/202420:00GlobeNewswire Inc.Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
03/09/202420:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
13/08/202420:42Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABOSAcumen Pharmaceuticals Inc
13/08/202411:48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABOSAcumen Pharmaceuticals Inc
13/08/202411:00GlobeNewswire Inc.Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business HighlightsNASDAQ:ABOSAcumen Pharmaceuticals Inc
06/08/202420:00GlobeNewswire Inc.Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
29/07/202411:00GlobeNewswire Inc.Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s DiseaseNASDAQ:ABOSAcumen Pharmaceuticals Inc
28/07/202411:30GlobeNewswire Inc.Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
10/06/202420:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
10/06/202420:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
10/06/202420:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
10/06/202420:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
10/06/202420:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
05/06/202420:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABOSAcumen Pharmaceuticals Inc
14/05/202420:47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABOSAcumen Pharmaceuticals Inc
14/05/202411:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABOSAcumen Pharmaceuticals Inc
14/05/202411:00GlobeNewswire Inc.Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:ABOSAcumen Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ABOS